150
Participants
Start Date
April 8, 2016
Primary Completion Date
September 1, 2020
Study Completion Date
September 1, 2020
Blood tests
"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
Transcranial Doppler Microemboli Detection Study
Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
Memorial Sloan Kettering Cancer Center, New York
New York-Presbyterian Hospital/Weill Cornell Medical Center, New York
University of California, Davis
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Weill Medical College of Cornell University
OTHER